Su Phyu
YOU?
Author Swipe
View article: IMMU-14. Focused ultrasound–mediated blood-brain barrier disruption, combined with antigen-presenting cell activation, promotes CNS antigen-specific T cell immunity and bypasses immunotherapy resistance mechanism in malignant brain tumors
IMMU-14. Focused ultrasound–mediated blood-brain barrier disruption, combined with antigen-presenting cell activation, promotes CNS antigen-specific T cell immunity and bypasses immunotherapy resistance mechanism in malignant brain tumors Open
The efficacy of Immunotherapies against malignant brain tumors—characterized by profound heterogeneity—remains limited. The brain’s anatomical barriers and immunosuppressive microenvironment impede immune cell trafficking and antigen prese…
View article: CNSC-15. TARGETING GLIOMA-NEURONAL CIRCUIT REMODELING TO OVERCOME IMMUNOSUPPRESSION: FUNCTIONAL AND THERAPEUTIC INSIGHTS
CNSC-15. TARGETING GLIOMA-NEURONAL CIRCUIT REMODELING TO OVERCOME IMMUNOSUPPRESSION: FUNCTIONAL AND THERAPEUTIC INSIGHTS Open
Neuronal activity profoundly influences glioblastoma (GBM) cell proliferation and invasion, while GBM actively remodels the surrounding neuronal circuitry. We recently demonstrated that intratumoral regions with heightened neuronal connect…
View article: Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model
Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model Open
Background While chimeric antigen receptor (CAR) T-cells are promising, there is a rapidly growing interest in developing other CAR-expressing immune cells. However, to date, no reported studies evaluated these cells side-by-side in immune…
View article: IMMU-28. LOW-INTENSITY PULSED ULTRASOUND COMBINED WITH POLY-ICLC AND INTERLEUKIN-2 UNLOCKS THE IMMUNE PRIVILEGE OF THE BRAIN BY PROMOTING EPITOPE SPREADING AND ACTIVATION OF CNS-SPECIFIC NAÏVE T CELLS
IMMU-28. LOW-INTENSITY PULSED ULTRASOUND COMBINED WITH POLY-ICLC AND INTERLEUKIN-2 UNLOCKS THE IMMUNE PRIVILEGE OF THE BRAIN BY PROMOTING EPITOPE SPREADING AND ACTIVATION OF CNS-SPECIFIC NAÏVE T CELLS Open
Immunotherapies targeting glioma, such as chimeric antigen receptor (CAR) T cell therapies, offer new therapeutic avenues; however, their application has yielded limited success in clinical trials so far. Due to the antigenic heterogeneity…
View article: Extracellular Vesicle (EV) Survivin for Cancer Diagnostics and Therapeutics: A Review
Extracellular Vesicle (EV) Survivin for Cancer Diagnostics and Therapeutics: A Review Open
Survivin, an important inhibitor of apoptosis protein, contributes to cancer cells’ resistance to apoptosis, proliferation, and survival. It is a promising biomarker and therapeutic target due to being highly expressed in cancer cells rela…
View article: IL-13Rα2/TGF-<b>β</b> bispecific CAR-T cells counter TGF-<b>β</b>-mediated immune suppression and potentiate anti-tumor responses in glioblastoma
IL-13Rα2/TGF-<b>β</b> bispecific CAR-T cells counter TGF-<b>β</b>-mediated immune suppression and potentiate anti-tumor responses in glioblastoma Open
Background Chimeric antigen receptor (CAR)-T cell therapies targeting glioblastoma (GBM)-associated antigens such as interleukin-13 receptor subunit alpha-2 (IL-13Rα2) have achieved limited clinical efficacy to date, in part due to an immu…
View article: A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives
A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives Open
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median overall survival of less than 2 years and a nearly 100% mortality rate under standard therapy that consists of surgery followed by combined radiochemotherap…
View article: Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders
Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders Open
Cancers and neurological disorders are two major types of diseases in humans. We developed the concept called the “Aberrant Cell Cycle Disease (ACCD)” due to the accumulating evidence that shows that two different diseases share the common…
View article: Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment
Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment Open
The efficacy of chimeric antigen receptor T cell (CAR-T) therapy has been limited against brain tumors to date. CAR-T cells infiltrating syngeneic intracerebral SB28 EGFRvIII gliomas revealed impaired mitochondrial ATP production and a mar…
View article: Enhancing CAR-T Cell Metabolism to Overcome Hypoxic Conditions in the Brain Tumor Microenvironment
Enhancing CAR-T Cell Metabolism to Overcome Hypoxic Conditions in the Brain Tumor Microenvironment Open
The efficacy of chimeric antigen receptor (CAR)-T therapy has been limited against brain tumors to date. CAR-T cells infiltrating syngeneic intracerebral SB28-EGFRvIII glioma revealed impaired mitochondrial ATP production and a markedly hy…
View article: IMMU-04. LOW-INTENSITY PULSED ULTRASOUND ENHANCES CAR T CELL THERAPY BY INDUCING TWO-WAY IMMUNE CELL TRAFFICKING – T CELL INTO TUMOR AND MYELOID CELL INTO PERIPHERY IN A SYNGENEIC MOUSE GLIOBLASTOMA MODEL
IMMU-04. LOW-INTENSITY PULSED ULTRASOUND ENHANCES CAR T CELL THERAPY BY INDUCING TWO-WAY IMMUNE CELL TRAFFICKING – T CELL INTO TUMOR AND MYELOID CELL INTO PERIPHERY IN A SYNGENEIC MOUSE GLIOBLASTOMA MODEL Open
Chimeric Antigen Receptor (CAR) T-cell therapy has been successful against hematological malignancies. However, it has not established efficacy in glioblastoma (GBM) patients. Significant challenges currently limiting the effectiveness of …
View article: CNSC-06. REDIRECTING IMMUNOSUPPRESSIVE GLIOMA MICROENVIRONMENT THROUGH PHARMACOLOGICAL INTERVENTION TARGETING NEURONAL ACTIVITY
CNSC-06. REDIRECTING IMMUNOSUPPRESSIVE GLIOMA MICROENVIRONMENT THROUGH PHARMACOLOGICAL INTERVENTION TARGETING NEURONAL ACTIVITY Open
Recent single-cell RNA-sequencing analyses have revealed a strong association between glioma-neuronal circuit remodeling and regional immunosuppression. Subsequent preclinical investigations using syngeneic tumor models demonstrated that g…
View article: EXTH-18. DEVELOPMENT OF A TRANSGENIC MOUSE MODEL ENABLING COMPARATIVE ANALYSIS OF CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING IMMUNE CELL POPULATIONS FOR CANCER IMMUNOTHERAPY
EXTH-18. DEVELOPMENT OF A TRANSGENIC MOUSE MODEL ENABLING COMPARATIVE ANALYSIS OF CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING IMMUNE CELL POPULATIONS FOR CANCER IMMUNOTHERAPY Open
We reported the creation of C57BL/6J-background transgenic (Tg) mice carrying the anti-epidermal growth factor receptor (EGFR)vIII-CAR with CD3z-CD28-4-1BB downstream of a Lox-Stop-Lox cassette in the Rosa26 locus. Breeding these mice with…
View article: 956 Glioma-neuronal circuit remodeling induces regional immunosuppression
956 Glioma-neuronal circuit remodeling induces regional immunosuppression Open
Background Glioblastomas remodel neuronal circuits.1 Moreover, direct synaptic connections between neurons and glioblastoma cells and glioblastoma- and neuron-derived paracrine growth factors promote glioblastoma growth and invasion.2–4 In…
View article: 277 SynNotch-CAR T cells demonstrate potent anti-tumor efficacy in a preclinical immunocompetent mouse model for glioblastoma
277 SynNotch-CAR T cells demonstrate potent anti-tumor efficacy in a preclinical immunocompetent mouse model for glioblastoma Open
Background Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor. Recent immunotherapy studies, including CAR T cells, have shown limited success in GBM due to multiple barriers, such as on-target off-tumor toxicit…
View article: 843 Intra-cerebral spinal fluid vaccination to facilitate antigen-specific T-cell responses in the CNS tumors
843 Intra-cerebral spinal fluid vaccination to facilitate antigen-specific T-cell responses in the CNS tumors Open
Background Immunotherapies such as immune checkpoint inhibitors and CAR-T therapies have revolutionized cancer treatment in recent years. However, the success of the immunotherapies has been only limited to a small percentage of patients a…
View article: Non-cell-autonomous cancer progression from chromosomal instability
Non-cell-autonomous cancer progression from chromosomal instability Open
Chromosomal instability (CIN) is a driver of cancer metastasis 1–4 , yet the extent to which this effect depends on the immune system remains unknown. Using ContactTracing—a newly developed, validated and benchmarked tool to infer the natu…
View article: The clinical and molecular significance associated with STING signaling in breast cancer
The clinical and molecular significance associated with STING signaling in breast cancer Open
STING signaling in cancer is a crucial component of response to immunotherapy and other anti-cancer treatments. Currently, there is no robust method of measuring STING activation in cancer. Here, we describe an immunohistochemistry-based a…
View article: Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism
Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism Open
Androgen receptor (AR) activation is the primary driving factor in prostate cancer which is initially responsive to castration but then becomes resistant (castration-resistant prostate cancer (CRPC)). CRPC cells still retain the functionin…
View article: Probing the PI3K/Akt/mTor pathway using 31P-NMR spectroscopy: routes to glycogen synthase kinase 3
Probing the PI3K/Akt/mTor pathway using 31P-NMR spectroscopy: routes to glycogen synthase kinase 3 Open
Akt is an intracellular signalling pathway that serves as an essential link between cell surface receptors and cellular processes including proliferation, development and survival. The pathway has many downstream targets including glycogen…
View article: Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells
Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells Open
This is the first study to show that treatment of breast cancer cells with metformin induces profound changes in phospholipid metabolism.